There has been steady progress in antisense technology over the past 14 years. We now have a far better appreciation of the attributes and limitations of the technology. Antisense oligonucleotides have been used to selectively inhibit thousands of genes in mammalian cells, hundreds, if not thousands, of genes in rodents and other species and multiple genes in humans. There are over 20 antisense drugs currently in clinical trials, several of which are showing promising results. Like any other class of drugs in development, there will continue to be successes and failures in the clinic. Despite some disappointments with the technology, it appears to be a valid platform for both drug discovery and as an experimental tool for functionalizing genes. Advances in the medicinal chemistry and formulation of antisense oligonucleotides will further enhance their therapeutic and commercial potential.
Introduction
Since the first description of oncogenes over 25 years ago (Stehelin et al., 1976) , there has been tremendous progress in our understanding of the roles different genes play in the oncogenesis process. Completing the sequencing of the human genome further enhances our ability to identify those genes that are important for development and maintenance of the malignant phenotype. These studies have created a wealth of potential molecular targets for drug discovery efforts. Unfortunately, the timelines to identify safe and effective drugs against specific molecular targets is long and not very efficient, resulting in delays in testing hypothesis. Furthermore, many of the genes of interest are not approachable by conventional means. As a result, there is still a large unmet medical need to identify and develop better therapeutics for the treatment of cancer. Antisense oligonucleotides represent a potential solution to some of these issues. The timelines for identification of an antisense oligonucleotide drug are very short and any nuclear-encoded gene may be targeted. The drugs exhibit a number of generic properties such as pharmacokinetics, toxicology and manufacturing that reduce the risk of failure in preclinical studies.
Currently, there is one antisense drug on the market, fomivirsen, used to treat CMV retinititis. Although there is some controversy of whether there will be additional antisense drugs on the market (Lebedeva and Stein, 2001) , the data reviewed in aggregate strongly suggest that the technology will deliver additional drugs. Like any drug discovery platform, antisense oligonucleotides will not be the 'magic bullet'. However, there has been tremendous progress in defining the attributes and limitations of the technology. This information can be used to exploit the attributes and avoid the limitations. Further improvements to the platform have made newer generation antisense drugs more attractive as research tools and as therapeutics. With the recent discovery of a new antisense mechanism, that is RNA interference, interest in antisense technology has been reinvigorated. This additional investment will further enhance the potential of the technology.
Antisense mechanism of action
Antisense oligonucleotides are designed to bind to RNA through Watson-Crick hybridization. In general, their size ranges from 12 to 25 nucleotides in length, with the majority of antisense oligonucleotides being 18-21 nucleotides in length. There are multiple mechanisms that can be exploited to inhibit the function of the RNA once the oligonucleotide binds to the target RNA (Crooke, 1999) . The best-characterized antisense mechanism results in cleavage of the targeted RNA by endogenous cellular nucleases, such as RNase H or the nuclease associated with the RNA interference mechanism. However, oligonucleotides that inhibit expression of the target gene by noncatalytic mechanisms, such as modulation of splicing or translation arrest, can also be potent and selective modulators of gene function.
RNase H is a family of ubiquitously expressed enzymes that cleave the RNA strand of an RNA-DNA heteroduplex, with at least two forms found in mammalian cells (Lima et al., 2001) . Antisense oligonucleotides that inhibit gene expression by an RNase H-dependent mechanism of action ( Figure 1 ) contain a continuous segment of at least five to seven DNAlike nucleotides to support RNase H activity (Monia et al., 1993; Wu et al., 1999) . Most of the antisense drugs currently in clinical trials utilize the RNase H mechanism (Table 1) . As such, oligonucleotides that work through an RNase H mechanism of action are well characterized in terms of their pharmacology, pharmacokinetics and toxicity.
Another RNase-dependent antisense mechanism that has recently received much attention is interference RNA or RNAi (Fire et al., 1998; Zamore, 2002) . Introduction of long double-stranded RNA (dsRNA) into eucaryotic cells leads to the sequence-specific degradation of homologous gene transcripts (RNAi). The larger RNA molecules are metabolized to shorter 20-21 nucleotide, double-stranded RNA fragments (siRNA) by an endogenous nuclease. The siRNA molecules in turn, bind to a protein complex, termed RNA-induced silencing complex (RISC), which unwinds the two strands of RNA molecules, allowing the antisense strand to bind to the targeted RNA molecule (Zamore et al., 2000; Zamore, 2002) . The RISC also contains an endonuclease activity, which hydrolyses the target RNA at the site where the antisense strand is bound. Recently, it has been shown that the 21-nucleotide siRNA duplexes can be directly transfected into mammalian cells, resulting in selective degradation of the targeted RNA (Figure 2) (Caplen et al., 2001; Elbashir et al., 2001) . RNA interference is an antisense mechanism of action, as ultimately a single-strand RNA molecule binds to the target RNA molecule by WatsonCrick base pairing rules and recruits a ribonuclease that degrades the target RNA. RNAi, in particular siRNA, has gained widespread acceptance as a methodology for gene functionalization in cultured mammalian cells. There are other RNases present in cells that may be exploited in a manner similar to RNase H or the dsRNase associated with RNAi. As an example, Wu et al. (1998) reported that single-stranded, phosphorothioate-modified oligoribonucleotides can promote selective loss of Ha-ras mRNA in human cells. The enzyme activity is consistent with a RNase III type enzyme and may be similar, if not identical, to the RNase III associated with the RISC (Wu et al., 1998; Martinez et al., 2002) . RNase L is another RNase enzyme that has been exploited for antisense applications (Torrence et al., 1993) . RNase L is a ribonuclease activated by 2 0 -5 0 -linked oligoadenylates generated in response to interferon activation. Linkage of 2 0 -5 0 oligoadenylate to an antisense oligonucleotide has been reported to promote selective cleavage of the targeted mRNA (Torrence et al., 1993; Leaman et al., 2002) . In addition to exploiting cellular nucleases to cleave the target RNA, oligonucleotides can be designed to chemically cleave the target RNA following hybridization. The best-characterized example of such oligonucleotides are ribozymes and DNAzymes (Breaker and Joyce, 1994; Cech and Uhlenbeck, 1994) . Currently, a ribozyme targeting VEGF is in phase I/II clinical trials (Weng and Usman, 2001) .
Antisense mechanisms that do not directly promote RNA degradation have also been described. Occupancy of the RNA (the receptor for the antisense oligonucleotide) by the oligonucleotide may sterically block translation of the RNA, that is translation arrest. We have found that only certain sites in the 5 0 -untranslated region of an mRNA are effective target sites for an antisense oligonucleotide that work through this mechanism. In particular, the 5 0 -terminus of a transcript appears to be a good target site for oligonucleotides for some molecular targets in that occupancy of this region prevents assembly of the ribosome on the RNA (Baker et al., 1997) .
Most mammalian RNAs undergo multiple post-or cotranscriptional processing steps in the cell nucleus including addition of a 5 0 -cap structure, splicing and polyadenylation. Regulation of RNA processing is another efficient mechanism in which oligonucleotides can be utilized to regulate gene expression. Studies have been published documenting that antisense oligonucleotides can be used to regulate RNA splicing in both cellbased assays and in rodent tissues (Dominski and Kole, 1993; Taylor et al., 1999b; Sazani et al., 2001; Mercatante et al., 2002; Sazani et al., 2002 ). An increasing number of alternatively spliced transcripts are recognized to encode functionally antagonistic proteins, and so this represents a viable approach to reversibly 'switch' protein function. One well-documented example is the apoptosis-regulating gene Bcl-x. The most commonly expressed splice variant (Bcl-xL) is known to be antiapoptotic; however, a variant of the gene lacking a portion of exon II is proapoptotic (BclxS). By designing oligonucleotides to regions surrounding the appropriate splice-site, we have succeeded in switching the splice variant produced, from Bcl-xL to Bcl-xS, and as a consequence sensitized the cells to chemotherapeutic agents (Taylor et al., 1999b; Mercatante et al., 2002) . Oligonucleotide binding to the premRNA can also be exploited to mask polyadenylation signals on the pre-mRNA, forcing the cell to utilize alternative poly A sites (Vickers et al., 2001) .
We have directly compared many of the antisense mechanisms described above in cell-based assays and have found that once optimized, oligonucleotides that work by each mechanism can be potent and selective inhibitors of gene expression. As an example in comparing RNase H-dependent oligonucleotides to siRNA oligonucleotides, we found that they exhibited similar potency, duration of action, target selectivity and efficiency (Vickers et al., 2003) . We have also found that oligonucleotides that modulate RNA splicing by steric mechanisms and oligonucleotides that prevent translation can be just as potent and effective inhibitors of gene expression as oligonucleotides that work by catalytic mechanisms (Baker et al., 1997) . These results suggest that catalytic turnover of the target RNA is not the ratelimiting step for antisense oligonucleotides. Our results suggest that for cell-based experiments, no single mechanism is vastly superior to other mechanisms, thus one should tailor the mechanism for the specific biological application. For in vivo applications, the RNase H-dependent mechanism has been broadly exploited to inhibit hundreds, if not thousands of genes in rodent, non-human primate and human tissues. As there is far less information available concerning how effectively the other antisense mechanisms work in vivo, it is premature to make any conclusions regarding their long-term potential for in vivo studies.
Figure 2 siRNA-dependent antisense mechanism. Doublestranded RNA oligonucleotides are transported across the plasma membrane, by either poorly characterized natural processes or by the use of facilitators such as cationic lipids (step 1). Once in the cytoplasm, the double-stranded RNA oligonucleotide is recognized and bound by a poorly defined protein complex termed RISC (step 2). A helicase activity unwinds the two RNA strands (step 3) and facilitates binding of the antisense strand to the target RNA (step 4). Once bound to the target RNA, a ribonuclease cleaves the targeted RNA (step 5). It is not known whether the ribonuclease also hydrolyses the antisense strand Oligonucleotide-based therapeutics for cancer NM Dean and CF Bennett
Antisense oligonucleotide chemistry
There are numerous oligonucleotide modifications that enhance the properties of antisense oligonucleotides. Some of the key issues that medicinal chemists have focused on are to enhance the potency of the oligonucleotide, change the pharmacokinetics, decrease toxicities and lower manufacturing costs. The greatest progress has been made in increasing potency of antisense oligonucleotides and improving the pharmacokinetics of unmodified nucleic acids. The most advanced oligonucleotide chemistry used for antisense drugs is phosphorothioate-modified oligodeoxynucleotides. Phosphorothioate-modified DNA differs from natural DNA in that one of the nonbridging oxygen atoms in phosphodiester linkage is substituted with sulfur. Phosphorothioate oligodeoxynucleotides are commercially available, easily synthesized, support RNase H activity, exhibit acceptable pharmacokinetics for systemic and local delivery and have not exhibited toxicities that limit their use in humans. However, there are opportunities to further enhance the 'drug-like' properties for this chemical class of oligonucleotides.
Modifications to the base, sugar and backbone have been identified that increase binding affinity for the target RNA (Freier and Altmann, 1997; Cook, 2001 ). The scope of heterocyclic modifications is somewhat limited as they provide the recognition points for the Watson-Crick base pairing. Modifications to pyrmidine bases such as a methyl group, propyne or G-clamp (Figure 3 ) have been shown to increase the binding affinity for both DNA and RNA (Wagner et al., 1993; Flanagan et al., 1999) . The 5-propynyl modification has proven to enhance the potency of phosphorothioate oligodeoxynucleotides in cell culture assays, but profound hepatoxicity limits their utility for in vivo application and human therapeutics (Shen et al., 2003) .
Modifications to the sugar have been particularly useful for both enhancing the potency of the oligonucleotide and enhancing their pharmacokinetics. The two most advanced modifications are 2 0 -O-methyl and 2 0 -Omethoxyethyl (MOE) (Figure 3) , with examples of each currently in clinical trials (Table 1) . These modifications result in a 3-10-fold increase in potency in cell-based assays compared to phosphorothioate oligodeoxynucleotides, an increase in nuclease resistance and decreased toxicity (Monia et al., 1993; Zhang et al., 1995; Zhao et al., 1995; Baker et al., 1997; McKay et al., 1999; Henry et al., 2000; Geary et al., 2001) . Uniform 2 0 -O-modified-oligonucleotides do not support an RNase H mechanism. This has led to the development of a chimeric strategy that focuses on the design of highaffinity, nuclease-resistant antisense oligonucleotides, which contain a 'gap' of contiguous phosphorothioatemodified oligodeoxynucleotides. These second-generation oligonucleotides have also retained the phosphorothioate modification to further increase nuclease resistance and as discussed below to enhance tissue distribution. Locked nucleic acids (LNA) represent an interesting new modification, with dramatic increases in hybridization properties with regard to DNA : RNA duplex and an increase in nuclease resistance (Wengel, 1999; Braasch and Corey, 2001) . It remains to be determined whether these properties will translate into improved efficacy in vivo.
There have been several modifications to the phosphate linkage or replacement of the phosphate and sugar. Such modifications increase the nuclease resistance of the oligonucleotide and potentially increase the binding affinity, but no longer support RNase activities. The most advanced class of oligonucleotides that have a linkage modification is the 'morpholino' modification that contains a neutral phorphorodiamidate linkage (Figure 3) (Summerton, 1999) . A morphilino antisense agent is currently in phase II clinical trials for restenosis, cancer and polycystic kidney disease. Peptide nucleic acid (PNA) is unique, in that the sugar-phosphate backbone is completely replaced with a peptide-based backbone (Figure 3) (Larsen et al., 1999) . This results in a polymer with a neutral backbone that has high affinity for complimentary nucleic acids and completely resistant to degradation by nuclease and peptidases. PNA has been investigated as an antisense agent, but these efforts have generally been frustrated by the poor cellular penetration and in vivo pharmacokinetic properties of PNA (Larsen et al., 1999; McMahon et al., 2002) . Recently, a four-lysine peptide conjugated to a PNA was found to provide robust in vivo activity when targeted to a splice junction (Sazani et al., 2002) . This data is highly encouraging, as it may provide a path to realizing the promise of PNA as an antisense therapeutic agent.
It should be noted that there is no single modification that covers all the desired properties for a modified oligonucleotide. Modifications have been identified which increase hybridization affinity of the oligonucleotide for its target RNA, increase nuclease resistance, Oligonucleotide-based therapeutics for cancer NM Dean and CF Bennett decrease toxicity, and alter pharmacokinetics. The ideal oligonucleotide may differ depending on the application. Therefore, it is important to be able to mix and match the various modifications so as to obtain the optimal oligonucleotide for the task at hand.
Antisense oligonucleotide drug discovery and target validation
The field of molecular biology has undergone a revolution in recent years, which has redefined the field as a data rich, as opposed to a data poor, discipline. Two early and key steps in the process of identifying appropriate targets for oncology drug discovery are to identify specific gene functions and develop an understanding of the role of a gene in contributing towards or maintaining a disease pathology (target validation). Antisense oligonucleotides can be used to selectively manipulate the expression of chosen gene or genes. Since mRNA detection and quantitation assays can be rapidly established for any gene, the most widely used antisense mechanisms that can accomplish this goal are antisense mechanisms that degrade target mRNA through either an RNase H or an siRNA-dependant mechanism.
Until recently, RNase H-dependent oligonucleotides were the most widely used mechanism of target gene downregulation by antisense oligonucleotides in cell culture experiments. However, with progress in siRNA, it is also becoming a popular method for gene functionalization in cells McManus and Sharp, 2002) . We routinely use oligonucleotides containing 2 0 -MOE-modified RNase H-dependent oligonucleotides because of their increased potency and longer duration of action (McKay et al., 1999) . There have been a large number of published studies using this modification to identify gene functions in multiple systems (for example (Li et al., 1999; Taylor et al., 1999a, b; Bulavin et al., 2001; Gottschalk et al., 2001; Urban et al., 2001; Pedersen et al., 2002) .
Historically, many studies using antisense approaches have focused on identifying functions for one, or at most a few genes at a time. However, recent advances in oligonucleotide synthesis and the application of highthroughput cell-culture-based assays have led to a more global, genome wide approach to gene function studies.
We have generated a library of optimized RNase H antisense inhibitors to approximately 3000 different genes. The generation of this library of antisense inhibitors has allowed us to develop a system to rapidly functionalize a large number of genes in a number of therapeutically relevant cell-culture-based assay systems. By combining these multiple diverse data sets, we can construct detailed functional networks, where relationships between genes is established by direct experimental manipulation of their expression. Related efforts using vector-based approaches have already been described for antisense and siRNA for use in either Candida albicans (De Backer et al., 2001) Antisense oligonucleotides are also a valuable technology to suppress gene expression in animals. Like tissue culture studies, the development of the 2 0 -MOEmodified antisense oligonucleotide has been of considerable value in facilitating our ability to generate potent and long-lasting agents to inhibit gene expression in animals. RNase H-supporting oligonucleotides containing this modification have been shown to distribute widely in the body after systemic dosing , resulting in specific gene knockdown in multiple tissues and cell types. These results can be obtained in the absence of any sophisticated formulations or delivery methods, the oligonucleotides are dissolved in aqueous buffers and administered by normal parenteral routes. The flexibility of this approach allows compounds to be used in accepted animal models of human disease, and gene expression levels to be titrated in a pharmacological manner. This approach has been used for a variety of therapeutic areas, including cancer. For example, we have examined the role of various apoptosis-related genes in mediated liver damage following activation through the TNF receptor or Fas in mouse models of fulminate hepatic failure (Zhang et al., 2000 (Zhang et al., , 2003 Yu et al., 2001) . To date, we have evaluated antisense oligonucleotides to over 30 genes in these models (H Zhang and N Dean, unpublished) . In each case, we documented that the antisense oligonucleotides selectively reduced the expression of the target gene in liver tissue. Fas was used as a model to establish the relationship between dosing, intrahepatocyte antisense concentration and Fas mRNA expression (Yu et al., 2001) . Fas expression could be reduced for up to 10 days after a single dose of antisense, and this inhibition was found to impact some, but not all forms of fulminate hepatic failure. Fas responses could also be regulated either in a positive or negative fashion by modulating the expression of either Bid or Bcl-xL in hepatocytes using antisense to block expression of each of these two genes individually or simultaneously (Zhang et al., 2003) .
Many studies have been published using RNase Hsupporting antisense in mouse models of cancer, the majority being xenograft experiments. Demonstrating antisense activity in these models has been challenging. The accumulation of antisense oligonucleotides in xenograft tissues is often low compared to other tissues. In addition, as discussed below, first generation antisense oligonucleotides have immune stimulatory effects in rodents, complicating interpretation of the results. Despite these issues, a number of recent publications have demonstrated compelling evidence for antitumor activity by chemically modified RNase H-dependent antisense oligonucleotides in xenograft models (Fennell et al., 2001; Miyake et al., 2001; Tortora et al., 2001; Kuss et al., 2002; Mohammad et al., 2002; Nylandsted et al., 2002; Hu et al., 2003; Lee et al., 2003; Thallinger et al., 2003) .
Despite the success of siRNA-based antisense at reducing gene expression in cultured cells, unmodified double-stranded RNA does not seem to be effective at reducing target gene expression tissues after systemic administration, unless delivered in relatively large, nonphysiological volumes of saline. For example, Song et al. (2003) were able to reduce Fas expression in hepatocytes using hydrodynamic administration of an siRNA antisense targeting Fas, and caspase 8 expression has been targeted in hepatocytes using the same approach (Zender et al., 2003) . Promising reports of siRNA oligonucleotides inhibiting growth of human tumor xenografts and inhibition of gene expression in the xenograft tissue are beginning to appear in the literature (Verma et al., 2003) . These early results are promising for siRNA oligonucleotides, and it is highly likely that chemical modifications will be developed that will further enhance the utility of these oligonucleotides for in vivo usage.
The process of identifying antisense oligonucleotides for target validation studies results in a pharmacophore with a well-understood mechanism of action, wellcharacterized distribution and a safe side effect profile which could be used as a human therapeutic. A significant advantage of antisense approaches to traditional small-molecule-based drug development is the ability to target any gene, irrespective of the protein structure. One example where this has been used to good effect is the gene survivin. Survivin is a very attractive target for cancer therapeutics, as the protein regulates cell proliferation, apoptosis and is known to be highly expressed in many tumor types (Altieri, 2003) . Considerable efforts have gone into developing smallmolecule inhibitors against survivin, however to date, no success has been reported. In contrast, we have successfully identified and characterized an antisense oligonucleotide inhibitor of survivin (Li et al., 1999; Chen et al., 2000) . Inhibition of survivin expression with this antisense results in polyploidy due to a defect in cytokinesis and ultimately induction of apoptosis. More recently, it has been shown that a survivin antisense oligonucleotide suppresses growth of xenografted tumors. These results have lead to a decision to develop the survivin antisense as a therapeutic for cancer.
Pharmacokinetics and toxicity of oligonucleotides
The pharmacokinetics for phosphorothioate oligodeoxynucleotides (first-generation oligonucleotides) and 2 0 -modified phosphorothioate oligonucleotides (secondgeneration oligonucleotides) have been extensively studied. Phosphorothioate oligodeoxynucleotides and chimeric 2 0 -modified/DNA phosphorothioate oligonucleotides rapidly distribute to whole tissue with distribution half-lives ranging from 30 to 60 min in vivo (Agrawal et al., 1991; Cossum et al., 1993; Zhang et al., 1995; Geary et al., 2001) . Distribution from plasma is largely due to distribution to peripheral tissues. In contrast, oligonucleotides that do not contain a phosphorothioate linkage, such as PNA, appear to be rapidly excreted in the urine (McMahon et al., 2002) . This difference in tissue distribution appears to be due largely to interactions with plasma proteins. First-and second-generation phosphorothioate oligonucleotides are broadly distributed to all peripheral tissues. The highest concentrations of oligonucleotides are found in the liver, kidney, spleen, lymph nodes and bone marrow with no measurable distribution to the brain (Agrawal et al., 1991 Cossum et al., 1993; Geary et al., 1997) . In general, the clearance rates result in half-lives of elimination ranging from 2 to 5 days in rodents and primates for first-generation oligonucleotides, with halflives increasing 5-10-fold for second-generation oligonucleotides Sewell et al., 2002) . The elimination half-lives for second-generation oligonucleotide suggest that once-weekly or even every two-week systemic dosing is feasible.
First-and second-generation phosphorothioate oligonucleotides not only distribute to tissues but also accumulate within cells in tissues (Butler et al., 1997; Graham et al., 1998; Yu et al., 2001) . At early time points after injection, phosphorothioate oligonucleotides appear to be associated with extracellular matrix and within cells; however, by 24 h, almost all of the oligonucleotide is found within cells in tissues (Butler et al., 1997) . The mechanism(s) by which oligonucleotides accumulate within cells following parenteral administration is currently unknown (Butler et al., 2000) .
In summary, pharmacokinetic studies of phosphorothioate oligonucleotides demonstrate that they are well absorbed from parenteral sites, distribute broadly to all peripheral tissues, do not cross the blood-brain barrier, and are eliminated primarily by slow metabolism. In general, the pharmacokinetic properties of this class of compounds appear to be largely driven by chemistry rather than sequence.
There are two broad categories of potential toxicities for antisense oligonucleotides; toxicities due to exaggerated pharmacology and toxicities due to nonantisense effects of the oligonucleotide. The former category of side effects results from the oligonucleotide binding to the desired target RNA or alternatively to nontarget RNA, producing an undesirable effect. Although this class of toxicity has not been a major issue for the technology, the potential for such toxicities can be further minimized by careful selection of the drug target and homology searches against human genomic databases. The second category of potential toxicities, that is nonantisense effects, has been documented at higher doses of oligonucleotides. This later category of toxicities is related to the chemical class of oligonucleotide and can also exhibit some sequence specificity.
Phosphorothioate oligodeoxynucleotides are the bestcharacterized class of oligonucleotides with regard to potential toxicities, having been examined extensively in a full range of acute, chronic and reproductive studies in rodents, lagomorphs and primates. In addition, well over 3000 patients have been exposed to phosphorothioate oligodeoxynucleotides in dozens of clinical trials. Phosphorothioate oligodeoxynucleotides have proven to be safer than originally anticipated, yet, like any other drug, they will produce nondesirable effects at higher doses. The most probable mechanism of the observed toxicities is the binding of oligodeoxynucleo-tides to proteins. It should be noted that different patterns of toxicity exist between species.
In rodents, the primary toxicities of first-generation oligonucleotides occur after prolonged exposure to the oligonucleotides at doses above 10 mg/kg and appear to be a result of pro-inflammatory effects of the oligonucleotides. These effects are characterized by splenomegaly, lymphoid hyperplasia and diffuse multiorgan mixed mononuclear cell infiltrates . Primates appear to be much less sensitive to these effects. Most phosphorothioate oligodeoxynucleotides produce some immune stimulation in rodents, however oligonucleotides containing specific sequence motifs can exhibit profound immune stimulation (Krieg et al., 1995; Rankin et al., 2001) . Immunostimulatory motifs include specific palindromic sequences and CpG (cytosine-guanosine) motifs (Rankin et al., 2001) . With careful oligonucleotide design, the immune stimulatory effects can be minimized. A major attribute of secondgeneration oligonucleotides is decreased immune stimulation in rodents Henry et al., 2000) .
In primates, the acute dose-limiting toxicities are a transient inhibition of the clotting cascade and the activation of the complement cascade (Galbraith et al., 1994; Henry et al., 1997a, b; Sheehan and Phan, 2001 ). Both of these toxicities are thought to be related to the polyanionic nature of the molecules and the binding of these compounds to specific protein factors in plasma and, as such, relate to peak plasma concentration. Prolongation of clotting times following administration of different phosphorothioate oligodeoxynucleotides is characterized by a transient concentration-dependent prolongation of activated partial thromboplastin times (aPTT) and has been observed in multiple species (Henry et al., 1997b) . Recent data suggest that there is a specific allosteric inhibition of the tenase complex as well as binding to thrombin (Sheehan and Phan, 2001) . Complement activation has been described primarily in non-human primates (Galbraith et al., 1994; Henry et al., 1997a) . To avoid the potential for complement activation, most studies have increased infusion times, or administered the drug by subcutaneous injection, with the goal of keeping peak plasma concentrations below a threshold concentration (Henry et al., 1997a) . It should be noted that phosphorothioate oligodeoxynucleotides have been administered by intravenous infusion to more than 3000 patients and volunteers without any significant indication of activation of the alternative complement cascade. Second-generation oligonucleotides also appear to have reduced propensity to activate complement in non-human primates Sewell et al., 2002) .
Clinical trials
To date, one antisense oligonucleotide has been approved by the FDA for local administration to treat CMV (fomivirsen) and greater than 20 other compounds are currently in various stages of clinical development, including 12 for the treatment of cancer (Table 1 ). The majority of the drugs in clinical trials are first-generation phosphorothioate oligodeoxynucleotides that are designed to inhibit gene expression through an RNase H mechanism. A comprehensive review of the antisense drugs currently in clinical development is beyond the scope of this review. We have chosen to briefly highlight four examples of antisense oligonucleotides in clinical trials as they represent two late-stage first-generation drugs and two early-stage second-generation drugs.
Oblimersen (G3139, Genasense)
Antiapoptotic proteins represent attractive targets for drug development in oncology, and G3139 is designed to inhibit one of the most well-characterized examples of these, BCL2. The oligonucleotide has been evaluated in multiple phase I/II studies with some evidence of activity, and has progressed into multiple phase II/III randomized studies in CLL, multiple myeloma, malignant melanoma, non-small-cell and small-cell lung cancer and prostate cancer. In addition, a number of nonrandomized studies are also underway (reviewed in (Banerjee, 2001; Tamm et al., 2001; Klasa et al., 2002) . Recent analysis of the phase III trial in malignant melanoma was encouraging with the antisense meeting some secondary end points. Analysis of all patients on an intent-to-treat (ITT) basis showed that the addition of Genasense to dacarbazine resulted in a median survival of 9.1 months, compared with 7.9 months for patients treated with dacarbazine alone (P ¼ 0.184). However, in patients treated per-protocol that completed a minimum follow-up of 12 months (N ¼ 480), the addition of Genasense resulted in a median survival of 10.1 months, compared with 8.1 months for dacarbazine alone, which was a significant improvement (P ¼ 0.035). In addition, for the ITT population (n ¼ 771), patients treated with Genasense plus dacarbazine showed a significant increase in median progression-free survival to 78 days, compared with 49 days for patients treated with dacarbazine alone (P ¼ 0.001). Patients treated with Genasense plus dacarbazine also achieved an antitumor response rate of 11.7% (using RECIST criteria), compared with 6.8% for patients treated with dacarbazine alone (P ¼ 0.019).
Affinitak (Isis 3521)
Affinitak is a first-generation antisense oligonucleotide that targets a member of the protein kinase C (PKC) family of serine/threonine kinases, PKC-alpha (Dean et al., 1994) . A number of phase I/II clinical trials were conducted with Affinitak in a variety of tumor types (Nemuanaitis et al., 1999; Mani et al., 2002) with some encouraging evidence of efficacy. Subsequently, two phase III studies in non-small-cell lung cancer were designed and conducted. In the first, 616 chemotherapy naı¨ve patients with either stage IIIb or stage IV cancers were administered Affinitak in combination with carboplatin and paclitaxel, or chemotherapy alone. Unfortunately, no difference was observed in primary log-rank analysis of the overall survival of the two groups (P ¼ 0.81). However, using a stratified log-rank statistical analysis that considered predefined variables, including duration of treatment, survival of the Affinitak-treated patients was greater than that of the patients in the control arm. Based on all 616 patients in the study, this result was statistically significant (P ¼ 0.048).
A survival analysis of the 256 patients who completed the prescribed course of chemotherapy showed a median survival of 17.3 months for Affinitak patients versus 14.4 months for patients receiving chemotherapy alone (P ¼ 0.054). The prescribed course of therapy was six cycles of treatment. In a second phase III study, Affinitak is being administered in combination with gemcitabine (Gemzar), also in patients with non-smallcell lung cancer.
GEM-231 (HYBO-165)
GEM-231 is an 18 mer second-generation chimeric phosphorothioate 2 0 -O-methyl/oligodeoxynucleotide targeting protein kinase A and is currently under development by Hybridon Inc. . A phase 1/2 trial of GEM231 in combination with irinotecan is being conducted. This chemotherapy combination was chosen based on promising preclinical data relating to this combination as a treatment of solid tumor cancers in mouse models (Wang et al., 2002) . A number of additional phase I/II studies are in progress.
OGX-011 (Isis 112989)
The first 2 0 -MOE modified antisense to enter clinical trials for cancer is OGX-011 which targets clusterin (Zellweger et al., 2001) . The safety and tolerability of OGX-011 is being evaluated in patients with prostate cancer in two phase I clinical trials by OncoGenex Technologies, Inc. The compound is being evaluated as a single agent in patients with high-risk prostate cancer and in combination with Taxotere in hormone-refractory prostate cancer.
Conclusions
There has been tremendous progress in antisense technology, although it has yet to deliver on its full potential. First-generation phosphorothioate oligodeoxynucleotides have proven to be valuable pharmacological tools for the researcher and have produced new therapies for the patient. Identification of improved second-and third-generation oligonucleotides with novel formulation will result in better therapies for patients. Although progress has been made for antisense technology, there are more questions that remain for the technology and opportunities to further improve upon the platform.
